The clinical observation of gemcitabine or vinorelbine combined with cisplatin in the treatment of advanced non-small cell lung cancer

Objective:To observe the efficacy,toxicity and side effects of gemcitable or vinorelbine cominld with cisplation in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods: Total of 80 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into two groups randomly, 40 in each group . Group gemcitabine with 40 patients received gemcitabine 1200 mg/m2 on d1,8 and cisplatin 80mg/m2 on d1,d3; group vinorelbine received vinorelbine 25 mg/m2 on d1,8 and cisplatin 80 mg/m2 on d1,d3. Both regiments had 21 days for each cycle, three weeks repeated and the efficacy was observed after 3 periods. Results: The effective rates of group gemcitabine and vinorelbine were 47.5% (19/40) and 45.0%(18/40) respectively, there was no significant difference (P0.05) between two groups. The median ailment development time were 4.9 and 4.1 months for group gemcitabine and vinorelbine ,respectively and there was sfafastic difference (P0.05). The 1-year survival rates were 42.5% for group gemcitabine and 40.0% for group vinorelbine, no significant difference (P0.05).Thrombocytopenia with group gemcitabine was higher than that of group vinorelbine but the leucopenian and alopecia and phlebitis in group gemcitabine were apparently lower than that in group vinorelbine. Conclusion: There was no significant difference between group gemcitabine and vinorelbine on efficacy ,median survival time and 1-year survival rate ,but there was a little advantage in group gemcitabine on median ailment development time. Both regimens are effective and well tolerated for patients with advanced non-small cell lung cancer.